2021

iCo Therapeutics Inc. Announces Upsized Subscription Receipt Private Placement

ico_admin2021-04-23T07:16:59+00:00April 23rd, 2021|2021, Press Releases|

iCo Therapeutics Inc. Agrees to a Business Combination with Satellos Bioscience Inc.

ico_admin2021-03-22T17:00:01+00:00March 22nd, 2021|2021, Press Releases|

iCo Therapeutics, Inc. announces agreement for in vivo testing of iCo- 019 on SARS-CoV-2

March 15, 2021, Vancouver, Canada - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or

ico_admin2021-03-16T00:37:52+00:00March 15th, 2021|2021, Press Releases|

iCo Therapeutics Inc. Announces Warrant Exercises

March 11, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or

ico_admin2021-03-12T01:01:51+00:00March 11th, 2021|2021, Press Releases|

iCo Therapeutics Inc. Proposes to Re-Price Warrants

Vancouver, British Columbia--(Newsfile Corp. - January 11, 2021) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB:

ico_admin2021-02-18T21:53:35+00:00January 11th, 2021|2021, Press Releases|

Oral Amphotericin B Candidate

ico_admin2021-02-21T21:40:18+00:00January 1st, 2021|2021, Presentations|